Memorial Sloan-Kettering Cancer Center 
Welcome,         Profile    Billing    Logout  
 24 Products   12 Diseases  24 Products   30 Trials   1033 News 
42 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vadacabtagene leraleucel (JCAR015) / BMS
2016-003400-31: Long-Term Follow-up Protocol for Subjects Treated with JCAR015

Ongoing
2
105
Europe
JCAR015, JCAR015, Suspension for injection
Celgene Corporation, Celgene Corporation
B-cell Acute Lymphoblastic Leukemia (ALL), A cancer of B-cells, a type of white blood cell responsible for producing antibodies, Diseases [C] - Immune System Diseases [C20]
 
 
NCT00466531: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Active, not recruiting
1/2
50
US
therapeutic autologous lymphocytes, cyclophosphamide
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Leukemia
12/26
12/26
NCT01044069: Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Checkmark In adult ALL at ASCO 2016
Jun 2016 - Jun 2016: In adult ALL at ASCO 2016
Checkmark Adult ALL at ASH 2015
Dec 2015 - Dec 2015: Adult ALL at ASH 2015
Checkmark For adult ALL at ASCO 2015
More
Active, not recruiting
1
93
US
gene-modified T cells targeted
Memorial Sloan Kettering Cancer Center
Leukemia, Acute Lymphoblastic Leukemia
01/26
01/26
NCT01840566: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Active, not recruiting
1
17
US
Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
04/26
04/26
NCT01860937: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Active, not recruiting
1
23
US
leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute
Relapsed B-Cell Acute Lymphoblastic Leukemia
05/26
05/26
zelavespib intravenous (PU-H71 IV) / Samus Therap
NCT01393509: The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Completed
1
47
US
PU-H71
Memorial Sloan Kettering Cancer Center
Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
03/23
03/23
NCT01269593: PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Active, not recruiting
1
63
US
PET Imaging using 124 IPUH71, Blood will be drawn at the multiple time points for pharmacokinetic & metabolite, analyses of 124I-PUH71. We anticipate these time points to be: approximately 10, minutes, 20 minutes, 30 minutes, 1-2 H, and 3-4 H, post-injection. Blood, samples will be obtained in the PET imaging suite.
Memorial Sloan Kettering Cancer Center, Samus Therapeutics
Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy
12/25
12/25
engineered autologous T cells / Memorial Sloan-Kettering Cancer Center
NCT01140373: Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Active, not recruiting
1
13
US
engineered autologous T cells, cyclophosphamide
Memorial Sloan Kettering Cancer Center, United States Department of Defense
Prostate Cancer
06/25
06/25
JCAR020 / BMS, Eureka Therap
NCT02498912: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Checkmark From trial for ovarian cancer
Apr 2015 - Apr 2015: From trial for ovarian cancer
Active, not recruiting
1
18
US
Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
Memorial Sloan Kettering Cancer Center, Stanford University, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Solid Tumors
08/25
08/25
ATA2271 / Memorial Sloan-Kettering Cancer Center
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruiting
1
14
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT06623396: A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Recruiting
1
18
US
M28z1XXPD1DNR CAR
Memorial Sloan Kettering Cancer Center
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
09/28
09/28
iCasp9M28z T cell infusion / Memorial Sloan-Kettering Cancer Center, Bellicum
NCT02414269: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Active, not recruiting
1/2
113
US
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Memorial Sloan Kettering Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
04/26
04/26
Zeltherva (galinpepimut-S) / SELLAS Life Sciences
REGAL, NCT04229979 / 2019-004134-42: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting
3
128
Europe, US, RoW
Galinpepimut-S, SLS-001, GPS, Azacitidine, Venetoclax, Decitabine, Cytarabine, Ara-C, Observation, GM-CSF, sargramostim, Montanide
Sellas Life Sciences Group
Acute Myeloid Leukemia
09/25
12/26
NCT01890980: Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Active, not recruiting
2
60
US
WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF
M.D. Anderson Cancer Center, U.S. Army Medical Research and Materiel Command, Memorial Sloan Kettering Cancer Center, Sellas Life Sciences Group
Malignant Pleural Mesothelioma
04/20
04/21
NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Completed
1/2
26
US
galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, pembrolizumab, MK-3475, Keytruda, Montanide, GM-CSF, sargramostim
Sellas Life Sciences Group, Merck Sharp & Dohme LLC, LumaBridge
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
07/22
10/22
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies

Active, not recruiting
1
15
RoW
3D189
3D Medicines
Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome
06/26
12/26
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Completed
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
11/24
11/24
NCT05593185: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Available
N/A
NA
Galinpepimut-S
Sellas Life Sciences Group
Acute Myeloid Leukemia, Myelodysplastic Syndromes
 
 
SER-155 / Memorial Sloan-Kettering Cancer Center, Seres Therap
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
NCT06801067: A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Recruiting
1
15
US
SER-155, Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated
Memorial Sloan Kettering Cancer Center
Diarrhea, Enterocolitis
01/27
01/27
Omblastys (131I-omburtamab) / Y-mAbs Therap
Trial 101, NCT03275402 / 2006-000287-84: 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Terminated
2/3
52
Europe, Japan, US
131I-omburtamab, 131I-8H9
Y-mAbs Therapeutics
Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
06/23
06/23
NCT04022213: A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Active, not recruiting
2
31
US
131 I-omburtamab, WAP-IMRT, Intensity Modulated Radiation Therapy
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
07/25
07/25
NCT04743661: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active, not recruiting
2
62
US
Irinotecan, CPT-11,, Temozolomide, Bevacizumab, rhuMAb VEGF, Avastin®), Omburtamab I-131, Liothyronine, SSKI, Potassium iodide, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Recurrent Medulloblastoma, Recurrent Ependymoma
10/29
10/30
NCT01099644: Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Terminated
1
54
US
131 I-8H9
Y-mAbs Therapeutics
Peritoneal Cancer
06/19
06/19
NCT00089245 / 2020-001590-68: Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Terminated
1
177
US
Iodine I 131 MOAB 8H9
Y-mAbs Therapeutics, Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
02/22
02/22
NCT05063357: 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Withdrawn
1
36
NA
131I-Omburtamab, Convention Enhanced Delivery
Y-mAbs Therapeutics, Labcorp Corporation of America Holdings, Inc, Invicro
DIPG
03/26
12/26
NCT05064306: 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Available
N/A
US
131I-omburtamab
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Central Nervous System/Leptomeningeal Neoplasms
 
 
Thalagen (autologous CD34+ cells transduced with TNS9.3.55) / San Rocco Therap, Memorial Sloan-Kettering Cancer Center
NCT01639690: ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

Active, not recruiting
1
10
Europe
Autologous CD34+ cells transduced with TNS9.3.55, Patient treatment with Filgrastim will last for up to 6 days with apheresis, collection on days 4 and 5 or days 5 or 6 if required. Reduced Intensity Conditioning will, consist of two days of busulfan treatment with an interval of two days prior to transplantation., Intravenous infusion of autologous CD34+ cells transduced with TNS9.3.55 will, be administered over 15-30 minutes in a volume of approximately 50 to 250 mL, on day 0. Subsequent infusions of autologous CD34+ cells transduced with TNS9.3.55, may be administered on day +1 or thereafter.
San Rocco Therapeutics
Confirmed Diagnosis of ß-thalassemia Major
07/25
07/25
FT819 / Fate Therap, Memorial Sloan-Kettering Cancer Center
FT819-102, NCT06308978: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting
1
244
US
FT819, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, Bendamustine
Fate Therapeutics
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
09/27
09/42
NCT04629729: FT819 in Subjects With B-cell Malignancies

Active, not recruiting
1
54
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
GD2-GD3 Vaccine / Y-mAbs Therap
NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Active, not recruiting
1/2
374
US
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
05/26
05/26
MCARH171 / BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center
NCT03070327: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Active, not recruiting
1
20
US
EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.
Memorial Sloan Kettering Cancer Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
02/26
02/26
MCARH109 / Eureka Therap, BMS, Memorial Sloan-Kettering Cancer Center, Sanofi
QUINTESSENTIAL, NCT06297226: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
2
175
Canada, Japan, US, RoW
Arlocabtagene Autoleucel (BMS-986393), CC-95266,, GPRC5D CAR T cells
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
06/27
06/32
NCT05431608: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Active, not recruiting
1
15
US
MCARH125, MCARH109
Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
06/25
06/25
NCT04555551: MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Active, not recruiting
1
17
US
Infusion of MCARH109 T cells
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
08/25
08/25
phenformin / Memorial Sloan-Kettering Cancer Center
NCT03026517: Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Completed
1
18
US
Dabrafenib, Trametinib, Phenformin
Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Weill Medical College of Cornell University
Melanoma
01/25
01/25
2141-V11 / Memorial Sloan-Kettering Cancer Center, Rockefeller University
NCT06347705: A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
2
99
US
2141-V11 Antibody
Memorial Sloan Kettering Cancer Center
Prostate Cancer
03/29
03/29
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
10/26
10/28
DKN-0993, NCT04059588: A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

Completed
1
16
US
2141 V-11
Rockefeller University
Cancer, Solid Tumor, Cancer of Skin
03/23
03/23
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
90
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
06/26
06/27
NCT05126472: Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Recruiting
1
55
US
anti-CD40 antibody 2141-V11
Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer Research Foundation, Rockefeller University
Non-muscle Invasive Bladder Cancer
11/26
11/26
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30
iso-fludelone (KOS-1803) / Memorial Sloan-Kettering Cancer Center
No trials found
MCARH109/MCARH125 CAR T / Memorial Sloan-Kettering Cancer Center
No trials found
MCARH125 / Memorial Sloan-Kettering Cancer Center
No trials found
CAR T cell therapy / Mnemo Therap
No trials found
Undisclosed GBM therapeutic / Origenis, Memorial Sloan-Kettering Cancer Center
No trials found
edatrexate (CGP-30694) / Memorial Sloan-Kettering Cancer Center, SRI International
No trials found
177Lu-DTPA-SC16 / Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine
No trials found
OrexiCAR T / CoImmune
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vadacabtagene leraleucel (JCAR015) / BMS
2016-003400-31: Long-Term Follow-up Protocol for Subjects Treated with JCAR015

Ongoing
2
105
Europe
JCAR015, JCAR015, Suspension for injection
Celgene Corporation, Celgene Corporation
B-cell Acute Lymphoblastic Leukemia (ALL), A cancer of B-cells, a type of white blood cell responsible for producing antibodies, Diseases [C] - Immune System Diseases [C20]
 
 
NCT00466531: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Active, not recruiting
1/2
50
US
therapeutic autologous lymphocytes, cyclophosphamide
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Leukemia
12/26
12/26
NCT01044069: Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Checkmark In adult ALL at ASCO 2016
Jun 2016 - Jun 2016: In adult ALL at ASCO 2016
Checkmark Adult ALL at ASH 2015
Dec 2015 - Dec 2015: Adult ALL at ASH 2015
Checkmark For adult ALL at ASCO 2015
More
Active, not recruiting
1
93
US
gene-modified T cells targeted
Memorial Sloan Kettering Cancer Center
Leukemia, Acute Lymphoblastic Leukemia
01/26
01/26
NCT01840566: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Active, not recruiting
1
17
US
Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
04/26
04/26
NCT01860937: T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Active, not recruiting
1
23
US
leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute
Relapsed B-Cell Acute Lymphoblastic Leukemia
05/26
05/26
zelavespib intravenous (PU-H71 IV) / Samus Therap
NCT01393509: The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Completed
1
47
US
PU-H71
Memorial Sloan Kettering Cancer Center
Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
03/23
03/23
NCT01269593: PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Active, not recruiting
1
63
US
PET Imaging using 124 IPUH71, Blood will be drawn at the multiple time points for pharmacokinetic & metabolite, analyses of 124I-PUH71. We anticipate these time points to be: approximately 10, minutes, 20 minutes, 30 minutes, 1-2 H, and 3-4 H, post-injection. Blood, samples will be obtained in the PET imaging suite.
Memorial Sloan Kettering Cancer Center, Samus Therapeutics
Non-Hodgkin's Lymphoma, Myeloma, Active Solid Malignancy
12/25
12/25
engineered autologous T cells / Memorial Sloan-Kettering Cancer Center
NCT01140373: Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Active, not recruiting
1
13
US
engineered autologous T cells, cyclophosphamide
Memorial Sloan Kettering Cancer Center, United States Department of Defense
Prostate Cancer
06/25
06/25
JCAR020 / BMS, Eureka Therap
NCT02498912: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Checkmark From trial for ovarian cancer
Apr 2015 - Apr 2015: From trial for ovarian cancer
Active, not recruiting
1
18
US
Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
Memorial Sloan Kettering Cancer Center, Stanford University, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Solid Tumors
08/25
08/25
ATA2271 / Memorial Sloan-Kettering Cancer Center
NCT04577326: Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Active, not recruiting
1
14
US
cyclophosphamide, CAR T cells
Memorial Sloan Kettering Cancer Center, Atara Biotherapeutics
Malignant Pleural Mesothelioma (MPM)
09/25
09/25
NCT06623396: A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Recruiting
1
18
US
M28z1XXPD1DNR CAR
Memorial Sloan Kettering Cancer Center
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
09/28
09/28
iCasp9M28z T cell infusion / Memorial Sloan-Kettering Cancer Center, Bellicum
NCT02414269: Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Active, not recruiting
1/2
113
US
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Memorial Sloan Kettering Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
04/26
04/26
Zeltherva (galinpepimut-S) / SELLAS Life Sciences
REGAL, NCT04229979 / 2019-004134-42: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting
3
128
Europe, US, RoW
Galinpepimut-S, SLS-001, GPS, Azacitidine, Venetoclax, Decitabine, Cytarabine, Ara-C, Observation, GM-CSF, sargramostim, Montanide
Sellas Life Sciences Group
Acute Myeloid Leukemia
09/25
12/26
NCT01890980: Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Active, not recruiting
2
60
US
WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF
M.D. Anderson Cancer Center, U.S. Army Medical Research and Materiel Command, Memorial Sloan Kettering Cancer Center, Sellas Life Sciences Group
Malignant Pleural Mesothelioma
04/20
04/21
NCT03761914: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Completed
1/2
26
US
galinpepimut-S, SLS-001, GPS, WT1 Analog Peptide Vaccine, pembrolizumab, MK-3475, Keytruda, Montanide, GM-CSF, sargramostim
Sellas Life Sciences Group, Merck Sharp & Dohme LLC, LumaBridge
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
07/22
10/22
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies

Active, not recruiting
1
15
RoW
3D189
3D Medicines
Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome
06/26
12/26
NCT04040231: Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Completed
1
10
US
Galinpepimut-S, Nivolumab, Sargramostim, GM-CSF
Memorial Sloan Kettering Cancer Center
Mesothelioma, Pleural Mesothelioma, Wilms Tumor
11/24
11/24
NCT05593185: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Available
N/A
NA
Galinpepimut-S
Sellas Life Sciences Group
Acute Myeloid Leukemia, Myelodysplastic Syndromes
 
 
SER-155 / Memorial Sloan-Kettering Cancer Center, Seres Therap
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
NCT06801067: A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Recruiting
1
15
US
SER-155, Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated
Memorial Sloan Kettering Cancer Center
Diarrhea, Enterocolitis
01/27
01/27
Omblastys (131I-omburtamab) / Y-mAbs Therap
Trial 101, NCT03275402 / 2006-000287-84: 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Terminated
2/3
52
Europe, Japan, US
131I-omburtamab, 131I-8H9
Y-mAbs Therapeutics
Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
06/23
06/23
NCT04022213: A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Active, not recruiting
2
31
US
131 I-omburtamab, WAP-IMRT, Intensity Modulated Radiation Therapy
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
07/25
07/25
NCT04743661: 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active, not recruiting
2
62
US
Irinotecan, CPT-11,, Temozolomide, Bevacizumab, rhuMAb VEGF, Avastin®), Omburtamab I-131, Liothyronine, SSKI, Potassium iodide, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Recurrent Medulloblastoma, Recurrent Ependymoma
10/29
10/30
NCT01099644: Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Terminated
1
54
US
131 I-8H9
Y-mAbs Therapeutics
Peritoneal Cancer
06/19
06/19
NCT00089245 / 2020-001590-68: Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Terminated
1
177
US
Iodine I 131 MOAB 8H9
Y-mAbs Therapeutics, Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
02/22
02/22
NCT05063357: 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Withdrawn
1
36
NA
131I-Omburtamab, Convention Enhanced Delivery
Y-mAbs Therapeutics, Labcorp Corporation of America Holdings, Inc, Invicro
DIPG
03/26
12/26
NCT05064306: 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Available
N/A
US
131I-omburtamab
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Central Nervous System/Leptomeningeal Neoplasms
 
 
Thalagen (autologous CD34+ cells transduced with TNS9.3.55) / San Rocco Therap, Memorial Sloan-Kettering Cancer Center
NCT01639690: ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

Active, not recruiting
1
10
Europe
Autologous CD34+ cells transduced with TNS9.3.55, Patient treatment with Filgrastim will last for up to 6 days with apheresis, collection on days 4 and 5 or days 5 or 6 if required. Reduced Intensity Conditioning will, consist of two days of busulfan treatment with an interval of two days prior to transplantation., Intravenous infusion of autologous CD34+ cells transduced with TNS9.3.55 will, be administered over 15-30 minutes in a volume of approximately 50 to 250 mL, on day 0. Subsequent infusions of autologous CD34+ cells transduced with TNS9.3.55, may be administered on day +1 or thereafter.
San Rocco Therapeutics
Confirmed Diagnosis of ß-thalassemia Major
07/25
07/25
FT819 / Fate Therap, Memorial Sloan-Kettering Cancer Center
FT819-102, NCT06308978: A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Recruiting
1
244
US
FT819, Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN, Bendamustine
Fate Therapeutics
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
09/27
09/42
NCT04629729: FT819 in Subjects With B-cell Malignancies

Active, not recruiting
1
54
US
FT819, Cyclophosphamide, Fludarabine, Fludara, IL-2, Interleukin-2, Bendamustine, Bendeka, Treanda
Fate Therapeutics
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
09/24
09/39
GD2-GD3 Vaccine / Y-mAbs Therap
NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Active, not recruiting
1/2
374
US
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Neuroblastoma
05/26
05/26
MCARH171 / BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center
NCT03070327: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Active, not recruiting
1
20
US
EGFRt/BCMA-41BBz CAR T cell, Cyclophosphamide, Lenalidomide.
Memorial Sloan Kettering Cancer Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
02/26
02/26
MCARH109 / Eureka Therap, BMS, Memorial Sloan-Kettering Cancer Center, Sanofi
QUINTESSENTIAL, NCT06297226: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
2
175
Canada, Japan, US, RoW
Arlocabtagene Autoleucel (BMS-986393), CC-95266,, GPRC5D CAR T cells
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
06/27
06/32
NCT05431608: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Active, not recruiting
1
15
US
MCARH125, MCARH109
Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
06/25
06/25
NCT04555551: MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma

Active, not recruiting
1
17
US
Infusion of MCARH109 T cells
Memorial Sloan Kettering Cancer Center
Multiple Myeloma
08/25
08/25
phenformin / Memorial Sloan-Kettering Cancer Center
NCT03026517: Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Completed
1
18
US
Dabrafenib, Trametinib, Phenformin
Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Weill Medical College of Cornell University
Melanoma
01/25
01/25
2141-V11 / Memorial Sloan-Kettering Cancer Center, Rockefeller University
NCT06347705: A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

Recruiting
2
99
US
2141-V11 Antibody
Memorial Sloan Kettering Cancer Center
Prostate Cancer
03/29
03/29
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
10/26
10/28
DKN-0993, NCT04059588: A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

Completed
1
16
US
2141 V-11
Rockefeller University
Cancer, Solid Tumor, Cancer of Skin
03/23
03/23
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
90
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
06/26
06/27
NCT05126472: Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Recruiting
1
55
US
anti-CD40 antibody 2141-V11
Memorial Sloan Kettering Cancer Center, Pin Down Bladder Cancer Research Foundation, Rockefeller University
Non-muscle Invasive Bladder Cancer
11/26
11/26
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in RGBM

Recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30
iso-fludelone (KOS-1803) / Memorial Sloan-Kettering Cancer Center
No trials found
MCARH109/MCARH125 CAR T / Memorial Sloan-Kettering Cancer Center
No trials found
MCARH125 / Memorial Sloan-Kettering Cancer Center
No trials found
CAR T cell therapy / Mnemo Therap
No trials found
Undisclosed GBM therapeutic / Origenis, Memorial Sloan-Kettering Cancer Center
No trials found
edatrexate (CGP-30694) / Memorial Sloan-Kettering Cancer Center, SRI International
No trials found
177Lu-DTPA-SC16 / Memorial Sloan-Kettering Cancer Center, Weill Cornell Medicine
No trials found
OrexiCAR T / CoImmune
No trials found

Download Options